Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.30 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13077768 | 0.87 | ALDH1A1 (0.37) | MAOAMAOBLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL8490160 | 0.85 | LMNA (0.50) | MAOAMAOBLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL9422695 | 0.81 | MAOA (0.46) | MAOAMAOBLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL13545545 | 0.78 | NPC1 (0.37) | LMNAALDH1A1SMN1; SMN2MAPTTSHR | |
| SCHEMBL14396043 | 0.78 | CYP1A2 (0.46) | MAOAMAOBLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL12948003 | 0.78 | ALDH1A1 (0.45) | MAOAMAOBLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL20079389 | 0.78 | LMNA (0.41) | MAOAMAOBLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL645262 | 0.77 | TSHR (0.48) | MAOAMAOBALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL3023046 | 0.76 | SMN1; SMN2 (0.43) | MAOAMAOBLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL13077769 | 0.73 | SMN1; SMN2 (0.44) | MAOAMAOBLMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120081482-A1 | Phthalocyanines and Their Use in Ink-Jet Printing | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2012-04-05 | — | — | US | disclosed |
| US-8057589-B2 | Comprising a phase change ink carrier and a phthalocyanine molecule; radiation curable ink | XEROX CORPORATION (US) | 2011-11-15 | — | — | US | disclosed |
| US-7781026-B2 | Ink compositions | XEROX CORPORATION (US) | 2010-08-24 | — | — | US | disclosed |
| US-7737270-B2 | Method for producing a pigment | CANON KABUSHIKI KAISHA (JP) | 2010-06-15 | — | — | US | disclosed |
| US-7692024-B2 | Gas generant compositions | TK HOLDINGS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-7544796-B2 | Colorant compounds | XEROX CORPORATION (US) | 2009-06-09 | — | — | US | disclosed |
| US-20080182984-A1 | METHOD FOR PRODUCING A PIGMENT | CANON KABUSHIKI KAISHA (JP) | 2008-07-31 | — | — | US | disclosed |
| US-20080152824-A1 | Phase change inks | XEROX CORPORATION | 2008-06-26 | — | — | US | disclosed |
| US-20080154032-A1 | Colorant compounds | XEROX CORPORATION | 2008-06-26 | — | — | US | disclosed |
| US-20080146795-A1 | Colorant compounds | XEROX CORPORATION | 2008-06-19 | — | — | US | disclosed |
| US-20080145558-A1 | Ink compositions | XEROX CORPORATION | 2008-06-19 | — | — | US | disclosed |
| US-20080110536-A1 | for automotive restraint systems; 2,3-Bis (tetrazolo-5-yl) nitrobenzene and 3,4-Bis (tetrazolo-5-yl) nitrobenzene claimed: reduced solids; one step reaction of 2,3-dicyano Nitrobenzene, Sodium azide and Zinc Bromide | DEUTSCHE BANK TRUST COMPANY AMERICAS, AS SECURITY AGENT FOR THE SECURED PARTIES | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080110536-A1 | for automotive restraint systems; 2,3-Bis (tetrazolo-5-yl) nitrobenzene and 3,4-Bis (tetrazolo-5-yl) nitrobenzene claimed: reduced solids; one step reaction of 2,3-dicyano Nitrobenzene, Sodium azide and Zinc Bromide | CBR1, KAT2B, CBR3 | MAOA 1779/4885MAOB 304/4885LMNA 4226/4885 |
| US-20120081482-A1 | Phthalocyanines and Their Use in Ink-Jet Printing | RB1, IDH1, CRY1 | MAOA 2688/4885MAOB 1901/4885LMNA 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.